Dafna Capital Management LLC Biocryst Pharmaceuticals Inc Transaction History
Dafna Capital Management LLC
- $389 Million
- Q3 2024
A detailed history of Dafna Capital Management LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Dafna Capital Management LLC holds 667,000 shares of BCRX stock, worth $4.87 Million. This represents 1.3% of its overall portfolio holdings.
Number of Shares
667,000
Previous 704,500
5.32%
Holding current value
$4.87 Million
Previous $4.35 Million
16.45%
% of portfolio
1.3%
Previous 1.12%
Shares
20 transactions
Others Institutions Holding BCRX
# of Institutions
279Shares Held
172MCall Options Held
625KPut Options Held
739K-
Vanguard Group Inc Valley Forge, PA20.3MShares$148 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$146 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$86.6 Million1.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$66.3 Million5.66% of portfolio
-
State Street Corp Boston, MA8.85MShares$64.6 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.36B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...